Mekiri Bio, Inc. filed a Form D with the Securities and Exchange Commission on 2025-10-16.
Mekiri Bio, Inc. filed a Form D notice of an exempt securities offering with the SEC on October 16, 2025. The filing reports $1M sold. Its industry group is Biotechnology. It names Debbie Lin (Executive Officer), Anita DiFazio (Executive Officer), Corey McCann (Director) (SEC Form D, October 16, 2025).
Is this your company?
Sell to companies like Mekiri Bio, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2025-10-16 · the record
Pitching, partnering or investing alongside them? See who really runs and owns Mekiri Bio, Inc.
Free to see. No signup.
More on the people and the money behind Mekiri Bio, Inc., from the filings we hold.
Biotechnology raises by companies based in Massachusetts, filed in October 2025, largest first.
Get an email when Mekiri Bio, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when Mekiri Bio, Inc. raises, hires or launches. No email unless you switch it on.
Watch Mekiri Bio, Inc. →Get the full cited report on Mekiri Bio, Inc.
What the filing shows about Mekiri Bio, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Mekiri Bio, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
The filing gives Mekiri Bio, Inc.'s address as 68 Harrison Avenue, Suite 605, Pmb 653323, Boston, MA 02111.
Saved here on this device in the meantime, so nothing is lost either way.
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
Mekiri Bio, Inc. is a registered filer with the SEC (CIK 2088062) and has filed since 2025-10-16. 1 filing is on record, the latest on 2025-10-16.
A filing shows the company exists and what it reports about itself. It is not an audit or a rating.
Mekiri Bio, Inc.'s Form D of 2025-10-16 names Debbie Lin, Anita DiFazio, Corey McCann and 1 more as its officers, directors or promoters.
Its new offerings report $1M sold across 1 offering, as its own filings state.
Trailing twelve months. 766 filings in Biotechnology, totalled by week.
Other than the payment of salaries and other compensation benefits and reimbursement of expenses, no officer, director, partner, manager or promoter will receive any payments from the proceeds of this offering.
Debbie Lin is named as Executive Officer on the Form D that Mekiri Bio, Inc. filed with the SEC on 16 October 2025, one of 4 people that filing names.
Anita DiFazio is named as Executive Officer on the Form D that Mekiri Bio, Inc. filed with the SEC on 16 October 2025, one of 4 people that filing names.
Corey McCann is named as Director on the Form D that Mekiri Bio, Inc. filed with the SEC on 16 October 2025, one of 4 people that filing names.
Aaron DiAntonio is named as Director on the Form D that Mekiri Bio, Inc. filed with the SEC on 16 October 2025, one of 4 people that filing names.
4 people named on the filing — 2 holding an executive role and 2 as directors only.
Named as of the 2025-10-16 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
No investor is drawn from a Form D — the form states how many invested and never who.
What the filing shows about Mekiri Bio, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Mekiri Bio, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Mekiri Bio, Inc. covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist Mekiri Bio, Inc.You get an alert in MentionFox the next time this company shows up.
If you're behind Mekiri Bio, Inc.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov.
Each opens in a new tab, filled in for Mekiri Bio, Inc.. With no account yet, you sign up free and land on the result.
On these lists: Biotech raises in Boston
Share your raise. This card is drawn from the company's own Form D filing, and sharing needs no account.
https://mentionfox.com/funding/mekiri-bio-inc-form-d-25000001